Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
14.71
-0.39 (-2.58%)
At close: Aug 1, 2025, 4:00 PM
14.59
-0.13 (-0.85%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.

The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson’s disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities.

It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin’s lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors.

The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.

Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.

Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.

Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.

Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Ltd.
Biohaven logo
CountryUnited States
Founded2013
IPO DateMay 4, 2017
IndustryBiotechnology
SectorHealthcare
Employees256
CEOVladimir Coric

Contact Details

Address:
215 Church Street
New Haven, Connecticut 06510
United States
Phone203 404 0410
Websitebiohaven.com

Stock Details

Ticker SymbolBHVN
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001935979
CUSIP NumberG11196105
ISIN NumberVGG1110E1079
SIC Code2834

Key Executives

NamePosition
Dr. Vladimir Coric M.D.Chairman and Chief Executive Officer
Matthew ButenChief Financial Officer
Dr. Bruce D. Car DACVP, Ph.D.Chief Scientific Officer
Kimberly GentileSenior Vice President of Clinical Operations
Deb YoungSenior Director of Regulatory Affairs and Operations
George C. Clark CPAVice President and Chief Accounting Officer
Jennifer PorcelliVice President of Investor Relations
Warren Volles J.D.General Counsel and Chief Legal Officer
Clifford Bechtold M.S.President, GM of Biohaven Ireland and Chief Compliance Officer
John TiltonChief Commercial Officer of Rare Diseases

Latest SEC Filings

DateTypeTitle
Jun 4, 20258-KCurrent Report
May 15, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
May 7, 20258-KCurrent Report
Apr 28, 20258-KCurrent Report
Mar 18, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 18, 2025DEF 14AOther definitive proxy statements
Mar 3, 20258-KCurrent Report